Donate
T1International and #insulin4all Advocates Score Major Win

T1International and #insulin4all Advocates Score Major Win

Facebook Google LinkedIn Twitter

Update: On March 14th, Novo Nordisk announced it would be lowering the list price of some of its insulins. On March 16th, Sanofi made a similar announcement

Following years of advocacy on affordable insulin for T1International, today Eli Lilly announced that vials of generic insulin Lispro will be available to all US customers for $25 effective May 1, 2023. Some other Eli Lilly insulins will also be made more affordable by the end of the year. Current list prices for insulin can be over $300 per vial.

“This decision for affordable insulin shows the power of grassroots advocacy and organizing,” said Elizabeth Pfiester, T1International’s Executive Director and a person living with type 1 diabetes. “The T1International community has been taking action and asking insulin manufacturers to put patients over profits for years. In October, T1International and people with diabetes demonstrated outside of Eli Lilly in Indianapolis, and shared a petition with thousands of signatures asking them to lower their list price of insulin. Today’s announcement from Eli Lilly to lower the list price of their authorized generic to $25 demonstrates the momentum and power behind the #insulin4all movement.”

We know that producing a vial of most analogue insulins costs between $3.69 and $6.16. The Big Three insulin manufacturers, Eli Lilly, Novo Nordisk, and Sanofi, raised the prices of their insulins in lock-step for years. This pharmaceutical company price gouging means that one in four people who rely on insulin ration due to high cost. Rationing has led to serious health complications and death. T1International calls on all insulin manufacturers to join together to lower all insulin list prices for all patients across the globe.

“In 2017, my son Alec passed away due to insulin rationing because of pharmaceutical greed. I have spoken to Eli Lilly executives several times in the years since, alongside others mourning unnecessary deaths,” said Nicole Smith-Holt T1International’s Ambassador and Leader of Families United for Affordable Insulin, a T1International group that provides outreach, support and guidance for families grieving the loss of loved ones impacted by the insulin price crisis. “I am grateful that they have finally taken this small step for insulin affordability. And, this announcement certainly won't erase Eli Lilly’s history and responsibility for the insulin price crisis.”

While Eli Lilly is also decreasing the price of two other insulin products, Humalog and Humulin, and launching the long-acting insulin interchangeable, Rezoglar, the list prices will still be out of reach for most patients. Eli Lilly and other insulin manufacturers have not announced recent price reductions for other insulins.

“Over 7 million Americans rely on injected insulin to stay alive and healthy. Many use more than one insulin dosage form or type,” said Fiona Mason, US National Director of T1International. “Securing $25 vials of short-acting insulin Lispro is a first step, but more needs to be done to ensure that all insulins and diabetes drugs and supplies are affordable and accessible to all.”

While insulin was first discovered 100 years ago, 1 in 2 people worldwide who rely on insulin to survive still struggle to afford or access insulin. Prices for insulin and diabetes management are inaccessible or unaffordable to many people living with the condition. For example, a person with diabetes in Kenya can spend 55% of their income on insulin and diabetes supplies. In other countries, insulin and supplies can cost as much as 80% of a family’s income or more.

“Here in Zimbabwe, accessing insulin can be challenging for patients and caregivers, sometimes costing 60% of monthly income,” said Laura Munyoro, who leads T1International’s #insulin4all Zimbabwe Chapter. “We run community-based health clinics for diabetes patients to provide support because insulin remains unaffordable to so many.”

Insulin affordability must come with insulin accessibility. Should the cost of insulin come down, manufacturers still need to work to ensure it is accessible to all who need it. Patient assistance programs can change at any time and are not available to all patients. In the past, generic insulin was not available in pharmacies.

“Insulin manufacturers have shown time and time again that they will put their CEO’s profits over patients’ lives,” said Kristen Whitney Daniels, co-Leader of T1International’s Federal Working Group and a person living with type 1 diabetes. “Eli Lilly can roll back this new price structure for Lispro at any time, or put in place other practices to limit its use. That’s why the government also needs to regulate insulin manufacturers to hold them accountable to ensuring the human right to insulin.”

If patients are facing an urgent need to access insulin, please see our insulin access and affordability resource.

These list price reductions come after years of dogged protest and activism by the #insulin4all diabetes patient community, launching the #insulin4all campaign, which has grown into a global movement. T1International supports #insulin4all Chapters and advocates in states across the U.S. and throughout the world.

T1International believes in a world where everyone with type 1 diabetes – no matter where they live – has everything they need to survive and achieve their dreams. The organization accepts no funding from pharmaceutical companies and provides advocacy training and support to volunteer advocates.

T1International is fighting for a world where no one with diabetes has to spend more than 5% of their income on insulin and blood glucose testing supplies each month. To get involved, sign up for updates about our Fight for Five campaign here.

Related posts:

A Letter from Liz: Big Changes at T1International

A Letter from Liz: Big Changes at T1International

As we begin 2024 and think about the plans for T1International this year and beyond, I wanted to share a personal update that is also a big organisational update. After over a decade of leading T1International, the time has come for me to transition from my role as Executive Director by the end of 2024. This decision was not made lightly. Read more

Levemir Discontinuation Impacts Patients

Levemir Discontinuation Impacts Patients

Only eight days of National Diabetes Awareness Month had passed this November when pharmaceutical company Novo Nordisk announced it would be pulling Levemir, a long-acting insulin that millions of insulin-dependent diabetic patients depend on, from the U.S. market. Read more

Eli Lilly: We Can't Find the $25 Insulin

Eli Lilly: We Can't Find the $25 Insulin

On March 1, Eli Lilly announced it would reduce the list prices of some of its insulins, including the generic Lispro, the same product as the name-brand Humalog. At a recent congressional hearing with the CEOs of insulin manufacturers and pharmacy benefit managers, David Ricks, Eli Lilly’s CEO, again celebrated that $25 insulin lispro was available to patients as of May 1. People with diabetes have worked tirelessly to reduce insulin costs for decades. So why aren’t we universally celebrating this announcement of lower prices? Because it is now the end of May, and I - and many others in my community - still haven’t been able to get the promised $25 insulin.
Read more

Patient Power Shines on US Federal and Global Stages

Patient Power Shines on US Federal and Global Stages

Advocates recently gathered in Washington, DC to attend the Senate HELP Committee Hearing entitled: The Need to Make Insulin Affordable for All Americans. The hearing, led by Chairman Senator Bernie Sanders, is the culmination of a decade of advocacy efforts by the #insulin4all community who have demanded public accountability for the global insulin price crisis. Read more

Health is Wealth: Direct Action Recap

Health is Wealth: Direct Action Recap

Voices from around the world were part of the T1International Rally and March outside Eli Lilly on October 24th, where #insulin4all activists demanded Eli Lilly immediately lower the list price of insulin and defended the lives of those who are rationing insulin just to survive. Read more

T1International Statement on Lilly & Novo's ''Generic Insulin''

T1International Statement on Lilly & Novo's ''Generic Insulin''

Patient-led activism is working. Today Eli Lilly announced that in response to criticism of high prices, the company will sell a version of Humalog insulin for half price. We are pleased to see this result after continual and dedicated efforts by non-pharma funded patient advocates to ensure list price of insulin goes down. While half-price is an improvement, it's still an unaffordable price for so many, considering most people need at least 2 vials each month.
Read more

Standing Up For My Daughter at Eli Lilly

Standing Up For My Daughter at Eli Lilly

I am not normally an angry or bitter person, but I am a mother who will fight for her children to the end. It infuriates me to tears to think that my child, or anyone’s child, has to pay extortionate prices for a medication that keeps them alive, especially a medication that is very inexpensive to manufacture. Read more

Raising My Voice at Eli Lilly

Raising My Voice at Eli Lilly

The whole experience of the demonstration showed me that I am not alone. My voice was heard. My daughter said throughout the day that she met great people. She also networked and built relationships with others who are supporting family members or close friends with diabetes, just as she supports me, and it showed her that we are all going through this battle together. We all have voices that matter. Read more

Nicole Smith-Holt Statement on Eli Lilly Helpline Announcement

Nicole Smith-Holt Statement on Eli Lilly Helpline Announcement

I vow to continue to fight for the rights and lives of all people with diabetes. I am doing all this in honor of my son, Alec Raeshawn Smith. I invite Lilly to work with me and non-industry funded organizations like T1International so that we can find real solutions to ensure #insulin4all. Mr. Mason, I am still waiting to hear from you. Read more

My Journey to Eli Lilly HQ for Answers

My Journey to Eli Lilly HQ for Answers

I was very nervous before going to confront the top executives of Eli Lilly and Company. But I was determined to tell them Alec’s story. They needed to hear from me what their insulin prices did to Alec, and are still doing to others. Read more

Taking a Stand at Eli Lilly Headquarters

Taking a Stand at Eli Lilly Headquarters

I joined dozens of people impacted by the rising cost of insulin in the USA in protest of those prices in front of Eli Lilly headquarters in Indianapolis, Indiana. Some had traveled many hours to join the protest, but one thing was made clear, we wanted to ensure that Eli Lilly heard our voices. We were passionate in our outcry for change and jointly understood that not saying anything is simply not an option.
Read more

Eli Lilly and Novo Nordisk: More Empty Promises

Eli Lilly and Novo Nordisk: More Empty Promises

Outrage at soaring insulin prices in the USA has been increasing. More patients and families are speaking out against unaffordable costs for life-saving medication than ever before. In response, two of the 'Big Three' insulin makers (who control over 90% of the insulin market) have recently made moves to combat this anger. Read more